Shilpa Medicare receives approval for 2-Deoxy-2-Glucose powder

The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients

Novo Nordisk’s CagriSema delivers strong Phase 3 results across REIMAGINE diabetes trials

Lilly’s oral GLP-1 drug Orforglipron outperforms Semaglutide in phase 3 diabetes trial

Based on the cumulative data from ACHIEVE-1 through ACHIEVE-5, Lilly plans to submit orforglipron for FDA approval for the treatment of type 2 diabetes by the end of the second quarter

Novo Nordisk's Zenagamtide shows strong HbA1c and weight loss benefits in phase II trial

Investigational once-weekly GLP-1 and amylin receptor agonist achieves up to 14.6% weight loss and significant blood sugar reductions

Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026

The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs

Novo Nordisk study exposes “hidden” inflammation driving cardio risk despite care

POSEIDON is among the largest global datasets to quantify this residual inflammatory burden

Zydus Wellness FY26 revenue climbs to Rs. 39.4 billion

Growth driven by strong performance across Sugar Free, RiteBite Max Protein, Everyuth, Glucon-D and Nutralite portfolios

Zeus Hygia launches Metaberine in Europe and US markets

Next-generation berberine formulation developed with BioSOLVE Technology targets metabolic health, blood sugar balance, and weight management

Mankind launches ‘Act at 30’ campaign to push early heart health screening

Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone

Dr. Reddy’s and Nestle Health Science launch Celevida GLP for optimized nutritional support

Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass